WorldCat Identities

王雯秋

Overview
Works: 5 works in 5 publications in 2 languages and 11 library holdings
Genres: Conversation and phrase books 
Roles: Author, Contributor
Publication Timeline
.
Most widely held works by 王雯秋
Qing qing song song shuo Ying yu = Conversations make easy by Wenqiu Wang( Book )

1 edition published in 2002 in Chinese and held by 4 WorldCat member libraries worldwide

Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial by Nicola G Ghazi( )

1 edition published in 2016 in English and held by 2 WorldCat member libraries worldwide

Meng jing shi yi( Book )

1 edition published in 2013 in Chinese and held by 2 WorldCat member libraries worldwide

Author Correction: Gene and mutation independent therapy via CRISPR-Cas9 mediated cellular reprogramming in rod photoreceptors by Eye Gene Therapy Consortium( )

1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide

SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

The SRPK family of kinases regulates pre-mRNA splicing by phosphorylating serine/arginine (SR)-rich splicing factors, signals splicing control in response to extracellular stimuli, and contributes to tumorigenesis, suggesting that these splicing kinases are potential therapeutic targets. Here, we report the development of the first irreversible SRPK inhibitor, SRPKIN-1, which is also the first kinase inhibitor that forms a covalent bond with a tyrosine phenol group in the ATP-binding pocket. Kinome-wide profiling demonstrates its selectivity for SRPK1/2, and SRPKIN-1 attenuates SR protein phosphorylation at submicromolar concentrations. Vascular endothelial growth factor (VEGF) is a known target for SRPK-regulated splicing and, relative to the first-generationSRPK inhibitor SRPIN340 or small interfering RNA-mediated SRPK knockdown, SRPKIN-1 is more potent in converting the pro-angiogenic VEGF-A165a to the anti-angiogenic VEGF-A165b isoform and in blocking laser-induced neovascularization in a murine retinal model. These findings encourage further development of SRPK inhibitors for treatment of age-related macular degeneration. Graphical Abstract: Highlights: SRPKIN-1 is the first irreversible inhibitor for SRPK1/2 kinase SRPKIN-1 is the first kinase inhibitor that targets a tyrosine residue covalently SRPKIN-1 inhibits phosphorylation of serine/arginine (SR)-rich splicing factor proteins SRPKIN-1 blocks angiogenesis in a CNV mouse model through VEGF alternative splicing Abstract : Hatcher etal. report the first irreversible SRPK1/2 inhibitor SRPKIN-1, which inhibits phosphorylation of serine/arginine (SR)-rich splicing factors protein and induces a VEGF alternative splicing isoform switch, leading to anti-angiogenesis in a wet CNV mouse model
 
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.81 (from 0.56 for Qing qing ... to 0.97 for Meng jing ...)

Associated Subjects
Languages